Feature Article

First-line Use of Antiangiogenic Agents in Unresectable Hepatocellular Carcinoma: A Double-Edged Sword?

Abstract: Treatment options for hepatocellular carcinoma (HCC), the most prevalent primary liver malignancy, have historically been limited, particularly in unresectable cases with underlying cirrhosis. Initial systemic […]

Feature Article

Revolutionizing Breast Cancer Treatment: The Promise of Antibody-Drug Conjugates

Abstract: Antibody-drug conjugates (ADCs) have significantly advanced the treatment of breast cancer by integrating the specificity of monoclonal antibodies with the cytotoxic efficacy of chemotherapy, thereby […]

Highlights

Highlights in Upper Gastrointestinal Cancer

From the 2025 American Society of Clinical Oncology Annual Meeting May 30-June 3, 2025 • Chicago, Illinois Addition of Durvalumab to Chemotherapy Improves Event-Free Survival in […]

Breast Cancer In Focus

Sequencing Antibody-Drug Conjugates in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

H&O How do you determine whether breast cancer is endocrine-resistant? JC An endocrine-sensitive patient is someone who has never received or has gone at least a […]

Prostate Cancer In Focus

The Addition of Darolutamide to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer

H&O What was the impetus for the ARANOTE trial? FS The ARANOTE trial1 was a follow-up to 2 other large phase 3 studies that looked at […]

Advances in LLM

Is Doublet Therapy Becoming a Standard of Care in Myelofibrosis?

H&O When is doublet therapy used in myelofibrosis? RR Single-agent Janus kinase (JAK) inhibitors are the mainstay of therapy in myelofibrosis, and a total of 4 […]

Advances in Drug Development

Reducing Drug Toxicity and Costs Through Off-Label Dosing

H&O What is wrong with the way doses are currently determined for oncology drugs? MR The US Food and Drug Administration (FDA) has approved many oncology […]

Letter From the Editor

Letter From the Editor: My Avatar, Myself: The Promise and Peril of AI in Medicine

A lot has changed since November 2022, when we published an interview with Dr Daniel Spratt about the use of artificial intelligence to help predict which […]